![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/0f7b0cea-8b0f-4c9a-bebf-7c70c3d1d072/15ff1a.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/08339483-5351-49f4-9caf-45ba5014d108/15ff1b.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![Frontiers | Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease Frontiers | Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease](https://www.frontiersin.org/files/Articles/493301/fphar-11-00146-HTML/image_m/fphar-11-00146-g001.jpg)
Frontiers | Chemokine Receptor 5, a Double-Edged Sword in Metabolic Syndrome and Cardiovascular Disease
Nanotechnology-Abetted Astaxanthin Formulations in Multimodel Therapeutic and Biomedical Applications | Journal of Medicinal Chemistry
![PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial](https://i1.rgstatic.net/publication/335550663_Ticagrelor_in_patients_with_diabetes_and_stable_coronary_artery_disease_with_a_history_of_previous_percutaneous_coronary_intervention_THEMIS-PCI_a_phase_3_placebo-controlled_randomised_trial/links/5dab261aa6fdccc99d91d5b6/largepreview.png)
PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
![Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile](https://i1.rgstatic.net/ii/profile.image/1001884793991170-1615879357772_Q512/Michael-Gonzalez-24.jpg)
Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile
![References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press](https://nap.nationalacademies.org/books/0309089964/gifmid/145.gif)